Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan-Reference-Cited by-同舟云学术

Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan

Published:2006-09-21 Issue:3 Volume:319 Page:1081-1087
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Iwai Masarsu,Li Huan-Sheng,Chen Rui,Shiuchi Tetsuya,Wu Lan,Min Li-Juan,Li Jian-Mei,Tsuda Masahiro,Suzuki Jun,Tomono Yumiko,Tomochika Hirokazu,Mogi Masaki,Horiuchi Masatsugu

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference33 articles.

1. Glucose and reactive oxygen species

2. Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats.

3. Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress

4. Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance

5. Tissue Angiotensin and Pathobiology of Vascular Disease

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of antihypertensive drugs on glucose metabolism;Diabetes, Obesity and Metabolism;2024-08-14

2. Progress in Quantitative Methods for Azelnidipine and Chlorthalidone: An Analytical Basis for a Recently Approved FDC;Current Pharmaceutical Analysis;2023-01

3. Chronic AT1 blockade improves hyperglycemia by decreasing adipocyte inflammation and decreasing hepatic PCK1 and G6PC1 expression in obese rats;American Journal of Physiology-Endocrinology and Metabolism;2021-11-01

Effects of Azelnidipine-Carboxymethylcellulose Gel on Healing of Full-Thickness Skin Wounds in Streptozotocin Induced Diabetic Rats

;Veterinary Medicine: Research and Reports;2019-12

5. Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): “Issues with hypertension studies in real-world practice”;Clinical and Experimental Hypertension;2019-11-22